2. Academic Validation
  3. Bavachin suppresses proliferation of laryngopharyngeal cancer by regulating the STAT3 and MAPK signaling pathways

Bavachin suppresses proliferation of laryngopharyngeal cancer by regulating the STAT3 and MAPK signaling pathways

  • J Cancer. 2025 Mar 31;16(7):2339-2352. doi: 10.7150/jca.92956.
Xiaonan Yang 1 2,  Zhimin Ding 1 3,  Hongting Hua 1,  Ruijia Gan 1,  Dongdong Meng 1,  Yan Zang 1 4,  Han Xiao 1,  Dong Wang 1,  Wanjin Jiang 5,  Dongyu Si 1,  Xiang Wei 6,  Mei Zhang 7,  Huabing Zhang 6,  Chaobing Gao 1
Affiliations

Affiliations

  • 1 Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
  • 2 Department of Otorhinolaryngology Head and Neck Surgery, Fuyang Women and Children's Hospital, Fuyang, 236000, China.
  • 3 Department of Otorhinolaryngology Head and Neck Surgery, The People's Hospital of Xuancheng City, Xuancheng, 242000, China.
  • 4 Department of Otorhinolaryngology Head and Neck Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
  • 5 Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Wannan Medical College, Wuhu, 241000, China.
  • 6 Department of Biochemistry & Molecular Biology, Metabolic Disease Research Center, School of Basic Medicine, Anhui Medical University, Hefei, 230022, China.
  • 7 Health Management Center, First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230022, China.
PMID: 40302804 DOI: 10.7150/jca.92956
Abstract

Purpose: The present study aimed to explore the underlying antitumor effects of bavachin on laryngopharyngeal Cancer in-vitro and in-vivo. Methods: Tu212 and FaDu cells were cultured in the incubator. Cells were treated with 0.1% DMSO (control group) and different concentrations of bavachin (experimental groups) for exploring the results of proliferation and Apoptosis. We revealed the underlying mechanism of bavachin on laryngopharyngeal Cancer through western blotting, qRT-PCR assay and immunofluorescence staining. Results: Bavachin could suppress the proliferation and migration of laryngopharyngeal Cancer cells in-vitro and in-vivo. Mechanistically, the results suggested that bavachin could downregulate the phosphorylation level of the signal transducer and activator of the transcription 3 (STAT3) and upregulate those of the mitogen-activated protein kinase (MAPK). Furthermore, bavachin also increased the expression level of Bax and suppressed those of Bcl-2, CDK4/6, and CyclinD1 in the laryngopharyngeal Cancer cells. Additionally, the study also identified that bavachin promoted Ferroptosis by decreasing the expression level of Glutathione Peroxidase 4 (GPX4) and increasing those of intracellular Reactive Oxygen Species (ROS) and glutathione (GSH). Conclusion: Taken together, these results demonstrated that bavachin could suppress the growth and migration of laryngopharyngeal Cancer cells and induce Apoptosis and cell cycle arrest of the laryngopharyngeal Cancer cells by regulating the MAPK/STAT3 signaling pathway. This study demonstrated that bavachin exhibited a clinical therapeutic potential for laryngopharyngeal Cancer.

Keywords

Apoptosis; Bavachin; Cell cycle; Laryngopharyngeal cancer; MAPK; STAT3.

Figures
Products